Nelmastobart and Capecitabine

Small molecule

Nelmastobart and Capecitabine is one of 30 small molecule programs targeting Metastatic Colorectal Cancer. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metastatic Colorectal CancerActive, not recruiting

Metastatic Colorectal CancerPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

698 competitors in Metastatic Colorectal Cancer

#DrugCompanyPhaseTrials

Vectibix

Amgen

Phase 3

45 2

Braftovi

Pfizer

Phase 3

11 3

Lumakras

Amgen

Phase 3

2 4

Theraplaza

BBiotech Pharmaceutical Co., Ltd.

Phase 3

2 5

Alinia

RRomark Laboratories L.C.

Phase 3

1 6

Fusilev

DDurata Therapeutics International BV (an Affiliate of Actavis, Inc.)

Phase 3

1 7

Cosela

PPharmacosmos A/S

Phase 3

1 8

Vatalanib

Novartis

Phase 3

2 9

PF-08634404

Pfizer

Phase 3

—10

Brivanib Alaninate

GGynecologic Oncology Group

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1/2Active, not recruiting

Metastatic Colorectal Cancer

NCT05990543

Clinical

Trials by Indication[1]

Metastatic Colorectal Cancer1 trial

Combination of Nelmastobart and Capecitabine Therapy in Metastatic Colorectal Cancer

Active, not recruiting·KKorea University Anam Hospital·Phase 1/2·NCT05990543·59 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Nelmastobart and Capecitabine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Nelmastobart and Capecitabine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Nelmastobart and Capecitabine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Korea University Anam Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: KKorea University Anam Hospital

Nelmastobart and Capecitabine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Metastatic Colorectal Cancer1 trial

References

Drug Info

Quick Facts

Related News